The combination of cobimetinib (MEK inhibitor) and vemurafenib (BRAF inhibitor) improved progression-free survival compared to vemurafenib monotherapy in patients with BRAFV600 mutant metastatic melanoma in a phase 3 clinical trial (12.3 months vs. 7.2 months; Ascierto et al., 2016). The gene discussed is MAP2K7; the disease is metastatic melanoma.